Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
https://www.biospace.com/article/releases/candel-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-can-2409-in-combination-with-valacyclovir-for-the-treatment-of-intermediate-high-risk-…